PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

被引：4

作者：

Brown, Fiona ^{[1
]}

Zhang, Yang ^{[2
]}

Hinterschied, Claire ^{[1
]}

Prouty, Alexander ^{[1
]}

Sloan, Shelby ^{[3
]}

Helmig-Mason, JoBeth ^{[3
]}

Chung, Ji Hyun ^{[1
]}

Vaddi, Kris ^{[2
]}

Chen-Kiang, Selina ^{[4
]}

Di Liberto, Maurizio ^{[4
]}

Alinari, Lapo ^{[1
]}

Scherle, Peggy ^{[2
]}

Lapalombella, Rosa ^{[3
]}

Paik, Jihye ^{[5
]}

Baiocchi, Robert A. ^{[6
]}

机构：

[1] Ohio State Univ, Div Hematol, Dept Internal Med, Coll Med, Columbus, OH USA

[2] Prelude Therapeut, Wilmington, DE USA

[3] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA

[4] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA

[5] Cornell Univ, Paik Lab, New York, NY 10021 USA

[6] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA

来源：

关键词：

D O I：

10.1182/blood-2019-130797

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

302

引用

页数：4